EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Caffeine for Prevention of Alzheimer’s Disease: Is the A2A Adenosine Receptor Its Target?

Stefania Merighi iD, Alessia Travagli, Manuela Nigro, Silvia Pasquini iD, Martina Cappello, Chiara Contri iD, Katia Varani iD, Fabrizio Vincenzi iD, Pier Andrea Borea, Stefania Gessi

Biomolecules · 2023

DOI: 10.3390/biom13060967 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, 2023. Verfasst von Stefania Merighi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medicine and for Romagna, University of Ferrara, 44121 Ferrara, Italy. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction, Neuroprotective Agents. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer’s disease (AD) is the most prevalent kind of dementia with roughly 135 million cases expected in the world by 2050. Unfortunately, current medications for the treatment of AD can only relieve symptoms but they do not act as disease-modifying agents that can stop the course of AD. Caffeine is one of the most widely used drugs in the world today, and a number of clinical studies suggest that drinking coffee may be good for health, especially in the fight against neurodegenerative conditions such as AD. Experimental works conducted “in vivo” and “in vitro” provide intriguing evidence that caffeine exerts its neuroprotective effects by antagonistically binding to A2A receptors (A2ARs), a subset of GPCRs that are triggered by the endogenous nucleoside adenosine. This review provides a summary of the scientific data supporting the critical role that A2ARs play in memory loss and cognitive decline, as well as the evidence supporting the protective benefits against neurodegeneration that may be attained by caffeine’s antagonistic action on these receptors. They are a novel and fascinating target for regulating and enhancing synaptic activity, achieving symptomatic and potentially disease-modifying effects, and protecting against neurodegeneration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseCognitive DysfunctionNeuroprotective AgentsHumansCaffeineCoffeeReceptors, Purinergic P1

Stichwörter der Autor:innen

A2A adenosine receptorAlzheimer’s diseaseamyloid betacaffeineneuroinflammationtherapeutic target

Substanzen

CaffeineCoffeeReceptors, Purinergic P1Neuroprotective Agents

Autor:innen und Institutionen

  • Department of Translational Medicine and for Romagna, University of Ferrara, 44121 Ferrara, Italy.
  • University of Ferrara, 44121 Ferrara, Italy.

ORCID-Profile: Stefania Merighi, Silvia Pasquini, Chiara Contri, Katia Varani, Fabrizio Vincenzi

Zitieren

APA

Merighi, S., Travagli, A., Nigro, M., Pasquini, S., Cappello, M., Contri, C., Varani, K., Vincenzi, F., Borea, P. A., & Gessi, S. (2023). Caffeine for Prevention of Alzheimer’s Disease: Is the A2A Adenosine Receptor Its Target?. Biomolecules. https://doi.org/10.3390/biom13060967

Vancouver

Merighi S, Travagli A, Nigro M, Pasquini S, Cappello M, Contri C, et al. Caffeine for Prevention of Alzheimer’s Disease: Is the A2A Adenosine Receptor Its Target?. Biomolecules. 2023. doi:10.3390/biom13060967

BibTeX
@article{Merighi2023,
  author = {Merighi, Stefania and Travagli, Alessia and Nigro, Manuela and Pasquini, Silvia and Cappello, Martina and Contri, Chiara and Varani, Katia and Vincenzi, Fabrizio and Borea, Pier Andrea and Gessi, Stefania},
  title = {Caffeine for Prevention of Alzheimer’s Disease: Is the A2A Adenosine Receptor Its Target?},
  journal = {Biomolecules},
  year = {2023},
  doi = {10.3390/biom13060967}
}
Kostenlos starten →